149 related articles for article (PubMed ID: 10230250)
1. Clinical and haemostatic effects of intravenous prostaglandin E1 therapy in patients with peripheral arterial occlusive disease.
Trifiletti A; Scamardi R; Pizzoleo MA; Sottilotta G; Soraci S; Attinà A; Bagnato L; Barbera N
Panminerva Med; 1999 Mar; 41(1):15-7. PubMed ID: 10230250
[TBL] [Abstract][Full Text] [Related]
2. Study of thrombinic activation indexes, in patients with lower limb critic ischaemia, before and after prostaglandin E1 therapy.
Trifiletti A; Bartolone S; Scamardi R; Pizzoleo MA; Attinà A; Sottilotta G; Canobbio V; Soraci S; Barbera N
Minerva Cardioangiol; 1999 Mar; 47(3):55-8. PubMed ID: 10389444
[TBL] [Abstract][Full Text] [Related]
3. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
Mangiafico RA; Malatino LS; Santonocito M; Messina R; Attinà T; Dell'Arte S; Sarnataro F
Int J Clin Pharmacol Ther; 1999 Jul; 37(7):347-51. PubMed ID: 10442509
[TBL] [Abstract][Full Text] [Related]
4. Intravenous prostaglandin E1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease.
Gianetti J; De Caterina M; De Cristofaro T; Ungaro B; Guercio RD; De Caterina R
Am Heart J; 2001 Oct; 142(4):733-9. PubMed ID: 11579367
[TBL] [Abstract][Full Text] [Related]
5. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease.
Matsui K; Ikeda U; Murakami Y; Yoshioka T; Shimada K
Am Heart J; 2003 Feb; 145(2):330-3. PubMed ID: 12595852
[TBL] [Abstract][Full Text] [Related]
6. Hemostasis and fibrinolysis in patients with intermittent claudication: effects of prostaglandin E1.
Weiss C; Regele S; Velich T; Bärtsch P; Weiss T
Prostaglandins Leukot Essent Fatty Acids; 2000 Nov; 63(5):271-7. PubMed ID: 11090253
[TBL] [Abstract][Full Text] [Related]
7. Haemostatic changes in patients with deep vein thrombosis.
Trifiletti A; Scamardi R; Pizzoleo MA; Soraci S; Nevoso A; Bagnato L; Barbera N
Panminerva Med; 1997 Mar; 39(1):21-3. PubMed ID: 9175416
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of intra-arterial and intravenous prostaglandin E1 infusions in occlusive arterial disease stage III/IV.
Balzer K; Rogatti W; Rüttgerodt K
Vasa Suppl; 1989; 28():31-8. PubMed ID: 2609242
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of haemostatic parameters and circadian variations of the haemostatic system in patients with systemic sclerosis and Raynaud's phenomenon.
Trifiletti A; Bartolone S; Scamardi R; Pizzoleo MA; Sottilotta G; Larosa D; Barbera N
Panminerva Med; 2000 Mar; 42(1):7-9. PubMed ID: 11019597
[TBL] [Abstract][Full Text] [Related]
10. Haemostatic parameters in patients with primitive venous hypertension.
Trifiletti A; Scamardi R; Pizzoleo MA; Nevoso A; Attina A; Soraci S; Bagnato L; Barbera N
Panminerva Med; 1997 Jun; 39(2):100-2. PubMed ID: 9230618
[TBL] [Abstract][Full Text] [Related]
11. Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease--a controlled randomised multicenter study.
Trübestein G; von Bary S; Breddin K; Diehm C; Gruss JD; Heinrich H; Horsch S; Kriessmann A; Maass U; Martin M
Vasa Suppl; 1989; 28():44-9. PubMed ID: 2692200
[TBL] [Abstract][Full Text] [Related]
12. [Did the arrival of prostanoids modify therapeutic indications in peripheral obstructive arteriopathies? Considerations based on our experience].
Cardia G; Tumolo R; Cuscito C
G Chir; 1997 May; 18(5):297-300. PubMed ID: 9312259
[TBL] [Abstract][Full Text] [Related]
13. Haemostatic effects of iloprost in patients with lower limb ischemia.
Trifiletti A; Scamardi R; Pizzoleo MA; Nevoso A; Soraci S; Bartolone S; Bagnato L; Barbera N
Panminerva Med; 1997 Sep; 39(3):202-4. PubMed ID: 9360422
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of prostaglandin E1 in the treatment of chronic pulmonary heart disease in the elderly people at the acute stage].
Huang CC; Xu M
Hunan Yi Ke Da Xue Xue Bao; 2001 Jun; 26(3):285-6. PubMed ID: 12536711
[TBL] [Abstract][Full Text] [Related]
15. [Prostaglandin E1 in decreased arterial perfusion].
Pilger E; Bertuch H; Stark G; Hönigl K
Wien Klin Wochenschr; 1988 Jul; 100(14):490-5. PubMed ID: 3062908
[TBL] [Abstract][Full Text] [Related]
16. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
Hesse WH; Rudofsky G; Peskar BA
Wien Klin Wochenschr; 1991; 103(18):554-7. PubMed ID: 1750222
[TBL] [Abstract][Full Text] [Related]
17. [The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia].
Nowakowska A
Ann Acad Med Stetin; 2005; 51(1):95-105. PubMed ID: 16496609
[TBL] [Abstract][Full Text] [Related]
18. [Changes of blood coagulative and fibrinolytic system and function of pulmonary vascular endothelium after therapy in patients with acute pulmonary thromboembolism].
Pang BS; Wang C; Lu Y; Yang YH; Xing GH; Mao YL; Huang XX; Zhai ZG
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(43):3074-8. PubMed ID: 18261355
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of intravenously applied prostaglandin E1.
Scheffler P; de la Hamette D; Leipnitz G
Vasa Suppl; 1989; 28():19-25. PubMed ID: 2609240
[TBL] [Abstract][Full Text] [Related]
20. Intra-arterial and intravenous administration of prostaglandin E1 cause different changes to skin microcirculation in patients with peripheral arterial occlusive disease.
Thum J; Caspary L; Creutzig A; Alexander K
Vasa; 1998 May; 27(2):100-5. PubMed ID: 9612114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
